CLGN (CollPlant Biotechnologies) Short-Term Debt: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLGN CollPlant Biotechnologies Ltd CLGN
35 GF Score
Price $0.31
GF Value $0.29
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is CollPlant Biotechnologies Short-Term Debt?

CollPlant Biotechnologies CLGN -3.13% 35 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates CLGN with a GF Score™ of 35/100 and a GF Value™ of $0.29 (Fairly Valued). The stock has 4 warning signs investors should review.

CollPlant Biotechnologies's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

CollPlant Biotechnologies Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

CollPlant Biotechnologies Short-Term Debt Related Terms

CollPlant Biotechnologies Short-Term Debt Historical Data

* Premium members only.

The historical data trend for CollPlant Biotechnologies's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CollPlant Biotechnologies Short-Term Debt Chart

CollPlant Biotechnologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CollPlant Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CLGN
35GF Score
CollPlant Biotechnologies Ltd CLGN
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
CollPlant Biotechnologies (CLGN) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is CollPlant Biotechnologies' Short-Term Debt too high?
CollPlant Biotechnologies' current Short-Term Debt is $0.00 Mil. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Short-Term Debt compare to CPMV and TCRT?
CollPlant Biotechnologies' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. CollPlant Biotechnologies's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Fairly Valued. The stock's GF Value™ is $0.29, compared to a current price of $0.31 — trading 6.9% above its estimated fair value. The current Short-Term Debt is $0.00 Mil. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?

Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued. The current stock price of $0.31 is trading 6.9% above its estimated GF Value™ of $0.29. GuruFocus considers CollPlant Biotechnologies to be Fairly Valued.

Key valuation signals for CLGN:

  • Short-Term Debt: $0.00 Mil
  • GF Value™: $0.29 vs. price of $0.31 (6.9% above fair value)
  • GF Score™: 35/100 with 4 warning signs

No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CollPlant Biotechnologies Business Description

Other Exchanges CPT:Germany
Address 4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score

Get the complete analysis for CLGN

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price
$0.29
GF Value